Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer — a pilot study
Platinum-based chemotherapy is the main type of I-line treatment of advanced and non-operative NSCLC patients without <em>EGFR</em> gene mutation. The excision repair cross-complementation group 1 (ERCC1) is an enzyme that executes the incision of the damaged DNA strand a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2012-04-01
|
| Series: | Folia Histochemica et Cytobiologica |
| Subjects: | |
| Online Access: | http://czasopisma.viamedica.pl/fhc/article/view/18700 |